Long term enzyme replacement therapy for Fabry disease: Effectiveness on kidney, heart and brain

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Rombach, Saskia M ^a   Smid, Bouwien E ^a   Bouwman, MacHtelt G ^a   Linthorst, Gabor E ^a   Dijkgraaf, Marcel G W ^a   Hollak, Carla E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; PLACEBO;

ADOLESCENT; ADULT; AGE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART VOLUME; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; WHITE MATTER LESION;

ADOLESCENT; ADULT; BRAIN; COHORT STUDIES; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HEART; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; ORGAN SIZE;

EID: 84875345645     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-47     Document Type: Article

References (37)

1. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L, N Engl J Med 1967 276 21 1163 1167 10.1056/NEJM196705252762101 6023233
2. Fabry's disease: alpha-galactosidase deficiency. Kint JA, Science 1970 167 922 1268 1269 10.1126/science.167.3922.1268 5411915
3. Alpha-Galactosidase A deficiency: Fabry disease. Desnick RJ, Ioannou YA, Eng CM, The metabolic and molecular bases of inherited disease. Volume 3 McGraw-Hill New York:, Scriver CR, Beaudet AL, Sly WS, 8 3733 3774
4. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. MacDermot KD, Holmes A, Miners AH, J Med Genet 38 11 769 775
5. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, N Engl J Med 1995 333 5 288 293 10.1056/NEJM199508033330504 7596372
6. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Biochim Biophys Acta 2010 1802 9 741 748 10.1016/j.bbadis.2010.05.003 20471476
7. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, JAMA 2001 285 21 2743 2749 10.1001/jama.285.21.2743 11386930
8. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, N Engl J Med 2001 345 1 9 16 10.1056/NEJM200107053450102 11439963
9. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Ann Intern Med 2007 146 2 77 86 10.7326/0003-4819-146-2-200701160-00148 17179052
10. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Hollak CE, Aerts JM, Ayme S, Manuel J, Orphanet J Rare Dis 2011 6 16 10.1186/1750-1172-6-16 21496291
11. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO, Nephrol Dial Transplant 2006 21 2 345 354 10.1093/ndt/gfi152 16204287
12. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, J Am Soc Nephrol 2007 18 5 1547 1557 10.1681/ASN.2006080816 17409312
13. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Circulation 2009 119 4 524 529 10.1161/CIRCULATIONAHA.108.794529 19153271
14. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, Health Technol Assess 2012 16 39 1 543 23199586
15. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, Proc Natl Acad Sci USA 2008 105 8 2812 2817 10.1073/pnas.0712309105 18287059
16. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, PLoS One 2007 2 7 598 10.1371/journal.pone. 0000598 17622343
17. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Sirrs S, Clarke JT, Bichet DG, Casey R, Lemoine K, Flowerdew G, Mol Genet Metab 2010 99 4 367 373 10.1016/j.ymgme.2009.11.001 20022777
18. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Nephrol Dial Transplant 2009 24 7 2102 2111 10.1093/ndt/gfp031 19218538
19. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, J Am Coll Cardiol 2011 57 9 1093 1099 10.1016/j.jacc.2010.11.018 21349401
20. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. Debette S, Markus HS, BMJ 2010 341 3666 10.1136/bmj.c3666 20660506
21. Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Linthorst GE, Germain DP, Hollak CE, Hughes D, Rolfs A, Wanner C, Mol Genet Metab 2011 102 1 99 102 10.1016/j.ymgme.2010.11.155 21123099
22. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Modification of Diet in Renal Disease Study Group, Ann Intern Med 1999 130 6 461 470 10.7326/0003-4819-130-6-199903160-00002 10075613
23. New equations to estimate GFR in children with CKD. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, J Am Soc Nephrol 2009 20 3 629 637 10.1681/ASN.2008030287 19158356
24. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Ann Intern Med 2003 139 2 137 147 10.7326/0003-4819-139-2-200307150-00013 12859163
25. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Am J Cardiol 1986 57 6 450 458 10.1016/0002-9149(86)90771-X 2936235
26. Left ventricular mass as a measure of preclinical hypertensive disease. Devereux RB, Koren MJ, de Simone G, Roman MJ, Laragh JH, Am J Hypertens 1992 5 6 Pt 2 175S 181S 1632938
27. Normal values of M-mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, Heart 2000 83 667 672 10.1136/heart.83.6.667 10814626
28. Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry. Gold H, Mirzaian M, Dekker N, Joao FM, Lugtenburg J, Codee JD, Clin Chem 2012 59 3 1 10 23204223
29. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den HM, Kidney Int 2007 72 5 632 637 10.1038/sj.ki.5002374 17568781
30. Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS-the Fabry Outcome Survey. Hughes DA, Barba Romero MA, Hollak CE, Giugliani R, Deegan PB, Mol Genet Metab 2011 103 3 207 14 10.1016/j.ymgme.2011.03.022 21543245
31. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Nephrol Dial Transplant 2012 27 3 1042 1049 10.1093/ndt/gfr420 21804088
32. Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. Cioffi G, Faggiano P, Lucci D, Di LA, Mureddu GF, Tarantini L, J Hypertens 2011 29 10 1994 2003 10.1097/HJH.0b013e32834acc6d 21881524
33. Heart function in patients with chronic glomerulonephritis and mildly to moderately impaired renal function. An echocardiographic study. Schroeder AP, Kristensen BO, Nielsen CB, Pedersen EB, Blood Press 1997 6 5 286 293 10.3109/08037059709062084 9359999
34. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Eur Heart J 2005 26 12 1221 1227 10.1093/eurheartj/ehi143 15728649
35. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Am J Cardiol 2006 97 10 1515 1518 10.1016/j.amjcard.2005.11.087 16679096
36. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, PLoS One 2012 7 10 47805 10.1371/journal.pone.0047805 23094092
37. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Lancet 2009 374 9706 1986 1996 10.1016/S0140-6736(09)61493-8 19959221